Skip to main content
main-content
Erschienen in: International Urogynecology Journal 5/2017

14.11.2016 | Original Article

Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder

verfasst von: Ali Riza Turkoglu, Neslihan Parmak Yener, Soner Coban, Muhammet Guzelsoy, Murat Demirbas, Hakan Demirci

Erschienen in: International Urogynecology Journal | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

To investigate the effect of solifenacin succinate on intraocular pressure (IOP) and dry eye in patients with overactive bladder (OAB).

Methods

The study was conducted prospectively between October 2014 and November 2015. A total of 93 female OAB patients with a mean age of 48.59 ± 11.28 years (range 19–75 years) were evaluated. A full ophthalmic examination, including the Schirmer I test and IOP measurements, was conducted. Solifenacin succinate (5 mg/day) was started orally. All procedures were repeated at the 4- and 12-week follow-up, and the effects and side effects were documented.

Results

No statistically significant difference was observed in IOP (p = 0.282, p = 0.189) and tear secretion (p = 0.122, p = 0.071) values from the baseline (day 0) to the 12th week in OAB patients using solifenacin succinate. Solifenacin succinate treatment was terminated in 3 patients owing to dry eye in 1 patient, increased IOP in 1 patient, and systemic side effects in 1 patient. Constipation and dry mouth at various rates were the most common systemic side effects observed.

Conclusions

Solifenacin succinate is useful in eliminating OAB symptoms in female patients, but can cause systemic side effects. It had no significant side effects on tear secretion (Schirmer I) and IOP. We concluded that solifenacin succinate could be reliably used in pure OAB patients without comorbidity in terms of dry eye and IOP. We believe that prospective studies with larger series are still needed to reach a definite conclusion.
Literatur
2.
Zurück zum Zitat Homma Y, Kakizaki H, Gotoh M, et al. Epidemiologic survey on urination. J Jpn Neurogenic Bladder Soc. 2003;14:266–77. Homma Y, Kakizaki H, Gotoh M, et al. Epidemiologic survey on urination. J Jpn Neurogenic Bladder Soc. 2003;14:266–77.
3.
Zurück zum Zitat Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor―which is the main mechanism of action? Eur Urol. 2003;43(1):1–5. CrossRefPubMed Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor―which is the main mechanism of action? Eur Urol. 2003;43(1):1–5. CrossRefPubMed
4.
Zurück zum Zitat Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144:1089–99. CrossRefPubMedPubMedCentral Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144:1089–99. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83:259–69. CrossRefPubMed Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83:259–69. CrossRefPubMed
6.
Zurück zum Zitat Lai HH, Boone T, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol. 2002;4:28–37. Lai HH, Boone T, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol. 2002;4:28–37.
7.
Zurück zum Zitat Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004;44:1023–33. CrossRefPubMed Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004;44:1023–33. CrossRefPubMed
8.
Zurück zum Zitat Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53. CrossRefPubMed Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53. CrossRefPubMed
9.
Zurück zum Zitat Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28:1935–46. CrossRefPubMed Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28:1935–46. CrossRefPubMed
10.
Zurück zum Zitat Sekeroglu MA, Hekimoglu E, Tasci Y, Dolen I, Arslan U. Ocular surface changes following oral anticholinergic use for overactive bladder. Cutan Ocul Toxicol. 2015;4:1–4. Sekeroglu MA, Hekimoglu E, Tasci Y, Dolen I, Arslan U. Ocular surface changes following oral anticholinergic use for overactive bladder. Cutan Ocul Toxicol. 2015;4:1–4.
11.
Zurück zum Zitat Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006. CrossRefPubMed Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006. CrossRefPubMed
12.
Zurück zum Zitat Ouslander JG, Blaustein J, Connor A, Orzeck S, Yong CL. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140(1):47–50. PubMed Ouslander JG, Blaustein J, Connor A, Orzeck S, Yong CL. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140(1):47–50. PubMed
13.
Zurück zum Zitat Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, Guyel S, Ozkardes H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol. 2005;59(5):588–92. CrossRefPubMedPubMedCentral Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, Guyel S, Ozkardes H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol. 2005;59(5):588–92. CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U. The effect of oral solifenacin succinate on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014;25(11):1479–82. CrossRefPubMed Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U. The effect of oral solifenacin succinate on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014;25(11):1479–82. CrossRefPubMed
15.
Zurück zum Zitat Sung VC, Corridan PG. Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol. 1998;81(4):634–5. CrossRefPubMed Sung VC, Corridan PG. Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol. 1998;81(4):634–5. CrossRefPubMed
16.
Zurück zum Zitat Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26(11):749–67. CrossRefPubMed Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26(11):749–67. CrossRefPubMed
17.
Zurück zum Zitat Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14(7):595–7. CrossRefPubMed Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14(7):595–7. CrossRefPubMed
18.
Zurück zum Zitat Bacman S, Perez Leiros C, Sterin-Borda LŞ, et al. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptor in patients with primary Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 1998;39:151–6. PubMed Bacman S, Perez Leiros C, Sterin-Borda LŞ, et al. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptor in patients with primary Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 1998;39:151–6. PubMed
19.
Zurück zum Zitat American Academy of Ophthalmology (2005). External disease and cornea. Basic and clinical science course section 8. San Francisco: AAO. p. 53–61. American Academy of Ophthalmology (2005). External disease and cornea. Basic and clinical science course section 8. San Francisco: AAO. p. 53–61.
Metadaten
Titel
Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder
verfasst von
Ali Riza Turkoglu
Neslihan Parmak Yener
Soner Coban
Muhammet Guzelsoy
Murat Demirbas
Hakan Demirci
Publikationsdatum
14.11.2016
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 5/2017
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-016-3199-x

Weitere Artikel der Ausgabe 5/2017

International Urogynecology Journal 5/2017 Zur Ausgabe

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Gynäkologie und bleiben Sie gut informiert – ganz bequem per eMail.